Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT05291156	TitleCAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy	Fase Fase 2	Date Added 2022-03-22	Ubicación Italia	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Avelumab, cetuximab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05286814	TitleM9241 en combinación con bomba de infusión de la arteria hepática (HAIP) y terapia sistémica para sujetos con cáncer colorrectal metastásico o colangiocarcinoma intrahepático	Fase Fase 2	Date Added 2022-03-18	Ubicación Maryland, United States	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT05277051	TitleFirst-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors	Fase Fase 1	Date Added 2022-03-14	Ubicación California, United States North Carolina, United States Oklahoma, United States Pennsylvania, United States Texas, United States Utah, United States Australia Canadá China Francia Japón Corea, República de España Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Dostarlimab, GSK4381562	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05243862	TitleSafety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.	Fase Fase 2	Date Added 2022-02-17	Ubicación Arizona, United States Florida, United States Minnesota, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Atezolizumab, PolyPEPI1018, Tecentriq	Etiquetas MSS/ MMRp
NCT ID NCT05239741	TitleStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)	Fase Fase 3	Date Added 2022-02-15	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas 5-Fluorouracil, Irinotecan, Leucovorin, oxaliplatin	Etiquetas MSI-H/ MMRd
NCT ID NCT05217446	TitleA Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer ( SEAMARK )	Fase Fase 2	Date Added 2022-02-01	Ubicación Arizona, United States California, United States Florida, United States Illinois, United States Minnesota, United States New York, United States Tennessee, United States Texas, United States Australia Bélgica Canadá Czechia Dinamarca Francia Alemania Italia Países Bajos Noruega Polonia Slovakia España Suecia Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas encorafenib, Braftovi, Erbitux, Keytruda	Etiquetas MSI-H/ MMRd
NCT ID NCT05215574	TitleEstudio de NGM831 como monoterapia y en combinación con pembrolizumab en tumores sólidos avanzados o metastásicos	Fase Fase 1	Date Added 2022-01-31	Ubicación Arizona, United States California, United States Florida, United States Michigan, United States New York, United States Oklahoma, United States Texas, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas NGM831, NGM831 plus pembrolizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05213195	TitleTerapia celular NKG2D CAR-NK en pacientes con cáncer colorrectal metastásico refractario	Fase Fase 1	Date Added 2022-01-28	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas NKG2D CAR-NK	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05205330	TitleUn estudio de fase Ib/IIa de CR6086 en combinación con balstilimab en pacientes con cáncer colorrectal metastásico pMMR-MSS	Fase Fase 2	Date Added 2022-01-25	Ubicación Italia	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas AGEN2034, Balstilimab, CR6086	Etiquetas MSS/ MMRp
NCT ID NCT05201612	TitlePembrolizumab y Olaparib en Cáncer Colorrectal Avanzado (CCR) Deficiente en Recombinación Homóloga (HRD).	Fase Fase 2	Date Added 2022-01-21	Ubicación España	Prior IO Allowed No	CRC-directed Sí	Status Unknown status	Drogas Olaparib, Pembrolizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp

Showing 111 to 120 of 299 entries